29 June 2018 - The MS Trust is very disappointed that NICE is unable to recommend ocrelizumab as an NHS treatment for early primary progressive MS.

In the appraisal consultation document, NICE acknowledges that there are no disease modifying treatments approved for primary progressive MS (PPMS), and that clinical trials have shown that ocrelizumab can slow the worsening of disability in PPMS.

However, NICE considers that the benefits gained from ocrelizumab treatment do not represent value for money to the NHS, when compared to the cost of routine NHS treatment currently provided for PPMS. The manufacturer’s proposal to provide ocrelizumab to the NHS at a reduced price while a clinical trial is on-going has also been rejected.

Read Multiple Sclerosis Trust press release